journal article·2024-03Open access

Truncated PD1 Engineered Gas‐Producing Extracellular Vesicles for Ultrasound Imaging and Subsequent Degradation of PDL1 in Tumor Cells

Siyan Zhang, Yuan Liang, Panpan Ji, Rui Zheng, Fan Lu, Guangdong Hou, Guodong Yang, Lijun Yuan

Advanced Science· Volume 11· Issue 12

Abstract

Abstract PDL1 blockade therapy holds great promise in cancer immunotherapy. Ultrasound imaging of PDL1 expression in the tumor is of great importance in predicting the therapeutic efficacy. As a proof‐of‐concept study, a novel ultrasound contrast agent has been innovated here to image and block PDL1 in the tumor tissue. Briefly, extracellular vesicles (EVs) are engineered to display truncated PD1 (tPD1) on the surface to bind PDL1 with high affinity by fusion to EV‐abundant transmembrane protein PTGFRN. The engineered EVs are then encapsulated with Ca(HCO3)2 via electroporation and designated as Gp‐EVtPD1, which would recognize PDL1 highly expressed cells and produce gas in the endosomes and lysosomes. On the one hand, the echogenic signal intensity correlates well with the PDL1 expression and immune response inhibition in the tumor. On the other hand, during the trajectory of Gp‐EVtPD1 in the recipient cells, tPD1 on the EV binds PDL1 and triggers the PDL1 endocytosis and degradation in endosomes/lysosomes in a sequential manner, and thus boosts the anti‐tumor immunity of cytotoxic T cells. In summary, Gp‐EVtPD1 serves as a novel ultrasound contrast agent and blocker of PDL1, which might be of great advantage in imaging PDL1 expression and conquering immune checkpoint blocker resistance.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · Photoacoustic and Ultrasonic Imaging · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Ultrasound Diagnostics Tangdu Hospital Fourth Military Medical University Xinsi Road No. 569th Xi'an 710038 P. R. China

Department of Digestive Surgery Xijing Hospital Fourth Military Medical University Shaanxi 710032 P. R. China

State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Department of Biochemistry and Molecular Biology Fourth Military Medical University Changlexi Road No. 169th Xi'an 710032 P. R. China

Department of Urology Xijing Hospital Fourth Military Medical University Xi'an 710032 P. R. China

Funding

National Natural Science Foundation of China

References (52)

Show source-provided references
1. 10.1038/nrc166910.1038/nrc1669 ↗
2. 10.1172/JCI8000910.1172/JCI80009 ↗
3. 10.1084/jem.191.4.62510.1084/jem.191.4.625 ↗
4. 10.1126/science.aaf149010.1126/science.aaf1490 ↗
5. 10.1056/NEJMoa140649810.1056/NEJMoa1406498 ↗
6. 10.1038/nrd141710.1038/nrd1417 ↗
7. 10.1161/01.CIR.97.5.47310.1161/01.CIR.97.5.473 ↗
8. 10.1016/j.biomaterials.2009.03.05110.1016/j.biomaterials.2009.03.051 ↗
9. 10.1002/adma.20160410510.1002/adma.201604105 ↗
10. 10.1021/acs.nanolett.6b0010810.1021/acs.nanolett.6b00108 ↗
11. 10.1021/nn403527r10.1021/nn403527r ↗
12. 10.1038/ncomms162710.1038/ncomms1627 ↗
13. 10.1002/anie.20120190210.1002/anie.201201902 ↗
14. 10.1016/j.jconrel.2011.01.02210.1016/j.jconrel.2011.01.022 ↗
15. 10.1002/anie.20090384110.1002/anie.200903841 ↗
16. 10.1016/j.biomaterials.2011.09.08210.1016/j.biomaterials.2011.09.082 ↗
17. 10.1002/wnan.159010.1002/wnan.1590 ↗
18. 10.1038/s41578-020-00277-610.1038/s41578-020-00277-6 ↗
19. 10.1124/pr.120.01955410.1124/pr.120.019554 ↗
20. 10.3390/pharmaceutics1208070510.3390/pharmaceutics12080705 ↗
21. 10.1126/sciadv.aav327010.1126/sciadv.aav3270 ↗
22. 10.1126/sciadv.aax884910.1126/sciadv.aax8849 ↗
23. 10.1039/D3BM00573A10.1039/D3BM00573A ↗
24. 10.1016/j.ymthe.2019.11.02010.1016/j.ymthe.2019.11.020 ↗
25. 10.1016/j.ymthe.2021.01.02010.1016/j.ymthe.2021.01.020 ↗
26. 10.1158/1078-0432.CCR-12-219910.1158/1078-0432.CCR-12-2199 ↗
27. 10.1016/j.cmet.2020.10.02110.1016/j.cmet.2020.10.021 ↗
28. 10.1016/j.pharmthera.2013.09.00410.1016/j.pharmthera.2013.09.004 ↗
29. 10.1016/j.biomaterials.2012.11.04810.1016/j.biomaterials.2012.11.048 ↗
30. 10.1021/acsami.2c0944310.1021/acsami.2c09443 ↗
31. 10.1021/acsnano.2c1084510.1021/acsnano.2c10845 ↗
32. 10.1016/j.ultrasmedbio.2012.10.00410.1016/j.ultrasmedbio.2012.10.004 ↗
33. 10.1016/j.addr.2022.11448010.1016/j.addr.2022.114480 ↗
34. 10.1038/s41565-019-0485-z10.1038/s41565-019-0485-z ↗
35. 10.1038/nnano.2011.16610.1038/nnano.2011.166 ↗
36. 10.1126/sciadv.aax286110.1126/sciadv.aax2861 ↗
37. 10.34133/research.010810.34133/research.0108 ↗
38. 10.1002/smll.20210804010.1002/smll.202108040 ↗
39. 10.1016/j.biomaterials.2021.12100010.1016/j.biomaterials.2021.121000 ↗
40. 10.1016/j.addr.2021.04.01310.1016/j.addr.2021.04.013 ↗
41. 10.3402/jev.v4.2631610.3402/jev.v4.26316 ↗
42. 10.1016/j.jconrel.2015.09.06210.1016/j.jconrel.2015.09.062 ↗
43. 10.1021/nn901883410.1021/nn9018834 ↗
44. 10.1002/smll.20220403110.1002/smll.202204031 ↗
45. 10.1016/j.actbio.2019.05.05410.1016/j.actbio.2019.05.054 ↗
46. 10.1016/j.imlet.2021.08.00410.1016/j.imlet.2021.08.004 ↗
47. 10.1126/sciadv.abd271210.1126/sciadv.abd2712 ↗
48. 10.3390/pharmaceutics1408158110.3390/pharmaceutics14081581 ↗
49. 10.1200/jco.2013.31.15_suppl.300010.1200/jco.2013.31.15_suppl.3000 ↗
50. 10.1016/j.celrep.2017.07.07510.1016/j.celrep.2017.07.075 ↗
51. 10.1016/j.molcel.2019.04.00510.1016/j.molcel.2019.04.005 ↗
52. 10.1016/j.ccell.2016.10.01010.1016/j.ccell.2016.10.010 ↗